Consensus guidelines for the management of plaque psoriasis

Archives of Dermatology

Volumn 148, Issue 1, 2012, Pages 95-102

  Hsu, Sylvia ^a   Papp, Kim Alexander ^q   Lebwohl, Mark G ^b   Bagel, Jerry ^c   Blauvelt, Andrew ^e   Duffin, Kristina Callis ^f   Crowley, Jeffrey ^g   Eichenfield, Lawrence F ^s   Feldman, Steven R ^h   Fiorentino, David F ⁱ   Gelfand, Joel M ^t   Gottlieb, Alice B ^k   Jacobsen, Carmen ^r   Kalb, Robert E ^l   Kavanaugh, Arthur ^s   Korman, Neil J ^m   Krueger, Gerald G ^f   Michelon, Melissa A ^k   Morison, Warwick ⁿ   Ritchlin, Christopher T ^u   Gold, Linda Stein ^o   Stone, Stephen P ^v   Strober, Bruce E ^d   Van Voorhees, Abby S ^j   Weiss, Stefan C ^p   Wanat, Karolyn ^j   Bebo, Bruce F ^r   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY AT BUFFALO   (United States)

^m CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Johns Hopkins Green Spring   (United States)

^o HENRY FORD HOSPITAL   (United States)

^p UNIVERSITY OF MIAMI   (United States)

^q Probity Medical Research   (United States)

^r National Psoriasis Foundation   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^v SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIVIRUS AGENT; CALCIPOTRIOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ADJUVANT THERAPY; ADVERSE OUTCOME; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; BLISTER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DEMYELINATING DISEASE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ELECTIVE SURGERY; ERYTHEMA; FOLIC ACID DEFICIENCY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOMA; MUCOSAL DRYNESS; NEOPLASM; PHOTOTHERAPY; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE INDEX; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURGICAL RISK; SYSTEMIC THERAPY; TUBERCULOSIS; VACCINATION; VIRUS INFECTION; VIRUS LOAD;

EID: 84855987158     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.1410     Document Type: Review

References (27)

1. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741. (Pubitemid 44547793)
2. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008; 128(5):1207-1211. (Pubitemid 351543220)
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
4. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFα rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007;48(2):87-101. (Pubitemid 47381571)
5. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58(1):106-115. (Pubitemid 350298146)
6. Saurat JH, Stingl G, Dubertret L, et al CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566. (Pubitemid 351239154)
7. Griffiths CE, Strober BE, van de Kerkhof P, et al ACCEPT Study Group. Comparison of ustekinumab and etanercept formoderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
8. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44(7):1515-1524. (Pubitemid 32651731)
9. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol. 1996;10(6):369-375. (Pubitemid 26364819)
10. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009; 60(5):824-837.
11. Krueger GG, Langley RG, Leonardi C, et al CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580-592. (Pubitemid 46220818)
12. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665- 1674. (Pubitemid 351671883)
13. Nijsten TEC, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol. 2003; 121(2):252-258. (Pubitemid 36969897)
14. Stern RS; PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol. 2001;44(5):755-761.
15. Lindelöf B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis: do the known risks now outweigh the benefits? Drug Saf. 1999;20(4):289-297. (Pubitemid 29196908)
16. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M; Canadian Calcipotriol and UVB Study Group. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. Dermatology. 2000;200(1):17-24. (Pubitemid 30088330)
17. Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. 2002;46(6):900-906.
18. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat. 2003;14(4):229-232. (Pubitemid 37474535)
19. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti- TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63(suppl 2):ii18-ii24. (Pubitemid 39424653)
20. Thaçi D, Pätzold S, Kaufmann R, Boehncke WH. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol. 2005;152(5):1048-1050. (Pubitemid 40704952)
21. Imafuku S, Tashiro A, Furue M. Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br J Dermatol. 2007;156(6):1367-1369. (Pubitemid 47029812)
22. Walker RE, Spooner KM, Kelly G, et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis. 1996;174(1):63-68. (Pubitemid 26255555)
23. Sha BE, Valdez H, Gelman RS, et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses. 2002; 18(9):661-665. (Pubitemid 35356586)
24. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18(2):257-264. (Pubitemid 38253448)
25. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004;25(5):331-335. (Pubitemid 39096154)
26. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835. (Pubitemid 44556851)
27. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527-1534. (Pubitemid 41815842)